Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCB-2022B
- Development stage
- Preclinical
- Lead developer
- Clover Biopharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SCB-2022B** is Clover Biopharmaceuticals' preclinical Omicron-derived SARS-CoV-2 protein-subunit vaccine antigen. It comprises a stabilized trimeric form of the SARS-CoV-2 Omicron spike glycoprotein produced using Clover's Trimer-Tag platform. In preclinical studies, it was evaluated as a monovalent Omicron vaccine and as one antigenic component of a bivalent vaccine with ancestral-strain SCB-2019; the study formulation used CpG 1018 and aluminum hydroxide adjuvants. Vaccination is intended to induce spike-directed neutralizing antibodies that block viral spike-mediated host-cell entry and prevent COVID-19. ([cloverbiopharma.com](https://www.cloverbiopharma.com/media/120.html))
- Other names
- SCB-2022B S-TrimerSCB2022B S-TrimerSCB 2022B S-Trimer
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SCB-2022B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCB-2022B.